Understanding the spatial characteristics of ovarian cancer
Official title: Spatial Radiogenomics of Ovarian Cancer: Implementation of a Lesion-specific 3D-printed Mould Pipeline in the Clinical Workflow for Image-guided Tissue Multi-sampling of Ovarian Tumours
Run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06324175 · Data updated 2026-11-12
This study is trying to see how different patterns in ovarian cancer tissue can help doctors create more personalized treatments for patients with High Grade Serous Ovarian Carcinoma.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 24 (estimated) |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Roma) |
| Status | Recruiting |
| Started | February 1, 2024 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | March 13, 2025 |
| Trial ID | NCT06324175 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with suspected High Grade Serous Ovarian Carcinoma scheduled for primary or interval debulking surgery.
✕Probably not a fit
Patients with early-stage ovarian cancer or non-serous high grade epithelial ovarian cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on High Grade Serous Ovarian Carcinoma (HGSOC) and aims to explore the biological spatial and temporal heterogeneity of the disease. By utilizing advanced imaging techniques and radiomics, the study seeks to capture complex patterns related to tissue microstructure, which are often overlooked in traditional histological evaluations. The integration of imaging data with clinical information, liquid biopsies, and genomic data may enhance the prediction of treatment responses and outcomes for patients. The goal is to develop personalized treatment strategies that address the molecular heterogeneity of tumors.
Why it matters
Potential benefit: If successful, this study could lead to more effective personalized treatments for patients with ovarian cancer.
How similar studies have gone: Other studies utilizing radiogenomics and imaging techniques have shown promise in improving treatment outcomes, suggesting this approach may be beneficial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with suspected HGSOC scheduled to undergo primary debulking surgery (PDS) or interval debulking surgery (IDS) will be recruited in the study. Prior histopathological confirmation of HGSOC will be required for IDS. The PDS cases without prior histological diagnosis will be selected on the basis of clinical suspicion (elevated serum CA125 and CT imaging). Exclusion Criteria: * Patients less than 18 Years old * Pregnancy * Non-serous high grade epithelial ovarian cancer (serous low grade, mucinous, clear cell carcinoma, endometrioid or non-epithelial ovarian cancer) * Early stage disease (I and II stage) * CT or MRI scan not available
Where it's running
-
Advanced Radiology Center
Roma, Italy Recruiting
Study contacts
- Principal investigator: Camilla Panico, Dr — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study coordinator: Camilla Panico, Dr.
- Email: camilla.panico@policlinicogemelli.it
- Phone: +390630158637
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.